In this paper, we build a new, simple, and interpretable mathematical model to describe the human glucose-insulin system. Our ultimate goal is the robust control of the blood-glucose (BG) level of individuals to a desired healthy range, by means of adjusting the amount of nutrition and/or external insulin appropriately. By constructing a simple yet flexible model class, with interpretable parameters, this general model can be specialized to work in different settings, such as type 2 diabetes mellitus (T2DM), intensive care unit (ICU) and type 1 diabetes mellitus (T1DM); different choices of appropriate model functions describing uptake of nutrition and removal of glucose differentiate between the models. In addition to data-driven decision-making and control, we believe the model is also useful for basic quantification of endocrine physiology. In both cases the available data is sparse and collected in clinical settings, major factors that have constrained our model choice to the simple form adopted.
Introduction

Background
Broadly speaking mathematical models of human physiology may serve one of two purposes: elucidation of the detailed mechanisms which comprise the complex systems underlying observed physiology; or prediction of outcomes from the complex system, for the purposes of medical intervention to ameliorate undesirable outcomes. In principle these two objectives interact: a model which explains the detailed mechanisms, if physiologically accurate and compatible with observed data, will of course be good for prediction. However, in many complex human physiological systems, basic understanding of the mechanisms involved is still developing. It is arguably the case that simple, interpretable, models which are trained on observed data may suffice for the purpose of prediction and control, in situations where the detailed underlying physiological mechanisms are not yet fully understood. The human glucose-insulin system provides an important example of a system where these issues come in to play. Moreover, depending on the purpose of the study and the structure and size of the available data, one needs to decide the required level of model fidelity, [37] . Here, because we aim to resolve the mean and variance of glucose dynamics, we ignore higher-fidelity physiology and build a lower-fidelity model in a way that it includes common, clinically-relevant inputs. The objective of this paper is to introduce a simple modeling framework for the human glucose-insulin system, which is interpretable, can be trained on observed data and then has predictive capability, in a predictive test data sense. In terms of flexibility and interpretability, there is a trade-off between data assimilation (DA) and machine learning (ML) approaches. In ML, we project data onto a complex, highly flexible function space. However, these algorithms often fail to be directly interpretable, limiting their potential for use, and creating the possibility of unwanted and unexplainable effects. On the other hand, in DA, we project data onto a model that is usually interpretable. Even though we use some flexibility relative to the ML algorithms, we gain some simplicity and interpretability that could be indispensable depending on the aims of the study. Hence, our modeling framework has the benefits of being interpretable and, like machine-learnt algorithms, of being guided by data.
Literature Review
Depending on their particular purposes, researchers have developed various mathematical models ranging from extremely simple to extremely complex to describe glucose metabolism in humans. Some of these models are developed to describe a very specific system, for example, a particular biological function of the pancreas [10, 30, 62] , whereas others have been developed to predict hypoglycemia [29, 49, 63] , glucose control [8, 11, 22, 28, 56, 72, 74] , or disease pathogenesis [31] . Some of these are continuous time models in the form of ordinary differential equations (ODEs) whilst others use machine learning: in [10, 30, 62] , the authors develop system of ODEs to model the phenomenon they investigate while for prediction of hypoglycemia, machine learning approaches are more common. To predict hypoglycemia, in [63] , various classification methods, such as random forest, support vector machine, k-nearest neighbors, are used. For the same purpose, in [49] a simple model, consisting of a logistic function, based on the mean and standard deviation of blood glucose (BG) measurements, is developed, and in [29] , a linear mixed effects model is used. On the other hand, for glucose control, a wide range of approaches are used, such as systems of ODEs [8] , combination of systems of ODEs and partial differential equations (PDEs) [28] , stochastic differential equations (SDEs) [72] , and various network models [11, 74] . On the other hand, there is also research to understand how T2DM patients and their health care providers reason about self-collected data, how this type of data should be used to make accurate future BG level forecasting, and what kind of strategies should be designed to maximize the usefulness of self-monitored data, [47, 48] . In [21] , a mobile application is developed for post-meal BG level forecasting with self-tracked data. It is also tested on two populations; one consisting of individuals who are educated about T2DM and familiar with mobile applications whereas the other consisting of individuals with low-literacy and limited mobile app usage. Both population find the mobile app useful in managing their disease. Another study investigating the reasoning mechanism of self-management strategies of T2DM patients, which is reported in [20] , shows the importance of effective visualizations in self-management of T2DM. On the other hand, in [4] , a DA framework is used for future BG level forecasting based on self-collected data. The results obtained with the DA approach is compared with other approaches such as Gaussian process model regression and with the prediction of expert diabetes educators. [5] is another study that a DA framework is developed as a computational method, which combines machine learning and mechanistic modeling to forecast future BG levels and to infer T2DM phenotypes.
One of the most popular quantitative models was developed in [9] and is now referred to as Bergman's Minimal model. This ODE model was developed with the purpose of estimating insulin sensitivity in the intravenous glucose-tolerance test (IVGTT) setting. Another widely-known ODE model was developed by Sturis et al. [62] with the aim of elucidating the cause of the ultradian (longperiod) oscillations of insulin and glucose. The experiments in [62] showed that the oscillations are caused by the delay process between the insulin and glucose production. This important observation led to the introduction of delay differential equations (DDEs) to model the long-period oscillations of insulin and glucose. On the other hand, in [31] , authors use a mathematical model to understand why it is easier to prevent type 2 diabetes mellitus (T2DM) than to cure it; the model is based on a negative feedback mechanism within a system of nonlinear ODEs, as an update to the pioneering model [65] , to describe β-cell mass, glucose, and insulin dynamics. Because they describe a specific aspect of the system, these models are relatively simple and easy to interpret. There are models, on the other hand, that aim to describe more complicated systems, with multiple and multi-scale interacting components, such as the events that occur during oral glucose ingestion [19, 41] . These models are comprised of a large number of ODEs or DDEs with many model parameters. Such models, which describe events in a very detailed manner, are typically used to understand the physiological network that results in the emergent behavior of the system. There are also machine learning models that could be used for the same purposes. Time series analysis could be used to identify and exploit systemic patterns in the data, and these patterns used to provide models for forecasting. In [13] , using autocorrelation analysis of continuous BG data, it is shown that future BG levels can be predicted by using recent time-history of the glucose. Following this result, simple autoregressive modeling is used for forecasting, based on continuous BG data collected from either type 1 or type 2 diabetic individuals, in [26, 59] . On the other hand, in [57] , a nonlinear computational model is used to estimate unmeasured variables and unknown model parameters based on sparse measurement data for glycemic management in ICU context.
The models cited in the previous paragraph are often developed in order to understand T2DM. There are a number of hurdles in using the resulting computational models for glycemic prediction and control, especially in the ICU setting. These include the wide variation in clinical response within and between patients, and resultant concerns about safety issues. In [73] , a model consisting of fractional polynomials and interaction terms is used with a linear regression approach to determine the initial insulin dose setting. In [67] Bergman's Minimal Model is modified so that it applies beyond the initial goal of explaining IVGTTs, and is instead applicable in the ICU setting. In this context it is referred to as the ICU Minimal Model (ICU-MM). In [43] , a control mechanism framework is developed that uses two compartment glucose-insulin model accounting for time-varying parameters.
On the other hand, there is a large body of research developed for similar purposes in type 1 diabetes mellitus (T1DM) context. One of areas these models are needed desperately is the artificial pancreas research. Researchers have long recognized the importance of efficient mathematical algorithm describing the glucose-insulin regulation, [14, 15, 18, 51, 52] . Indeed, in [14] and [51] , mathematical model is explicitly counted as one of the main components of artificial pancreas development. In all these works and many others, [24, 25, 40, 64] , that are focused on closed-loop-control of BG levels of T1DM patients, the amount of insulin to be infused via a pump is decided based on mainly the continuous glucose measurement (CGM). Hence, the mathematical models mostly describe the glucose-insulin regulation without incorporating any nutrition information. However, since nutrition is one of the main drivers of the BG level, developing models accounting for nutrition factor and using these models within the human-in-the-loop control systems for tight glycemic management in T1DM setting may have the potential to advance current glycemic management results and reduce the possibility of diabetes-related complications.
In all of the models referred to in the preceding literature review, parameters enter and play an important role in making predictions with the model, yet may be difficult to determine, as they are not directly measurable; furthermore, their values will vary from one patient to another. There are two overarching approaches to learning about parameters: optimization in which a model-data mismatch is minimized to determine parameters [23] ; and the Bayesian approach [39] in which the distribution on the parameters, given the data and given the assumed (noisy) model-data framework, is computed. Generally speaking the Bayesian approach provides more information as it gives not only parameter estimates, but uncertainties; this can be very useful in biomedical prediction as it may be used to predict, and hence avoid, rare events with extreme consequences. On the other hand the Bayesian approach is typically more costly as it requires determining an entire distribution and not just a point. The two are linked through the negative logarithm of the posterior distribution on the parameters, which is a penalized model-data mismatch functional. In [67] parameter estimation is performed based on surgical ICU data using a standard least-squares approach. In [33] , building on an adaptive modeling approach introduced in [67] , the authors use the ICU-MM to predict BG levels of patients over a moving time interval that starts right after the interval used for parameter estimation, employing a nonlinear least-squares approach. In [7] , the authors employ hybrid Newton observer design to predict BG levels of ICU patients within the framework of the ICU-MM; this is a method introduced in [12] to obtain numerical solution of a system of nonlinear ODEs through simulation by using Newton's method and eliminating the dependence on the exact discrete-time model when this exact model is not known analytically. On the other hand, in [34] , the authors develop a mechanistic model consisting of five submodels describing glucose regulation in critical care. They adopt a Bayesian approach in which the prior (regularizing) distribution is formed based on the both prior expert knowledge and routinely collected ICU data. By this approach, time-invariant model parameters, as well as a time-varying model parameter which represents the temporal variation in insulin sensitivity, are estimated. Another mathematical model consisting of ODEs is developed in [70] in which, with the exception of the time-varying insulin sensitivity parameter, all the model parameters are fixed at reasonable values known a priori. Then, the insulin sensitivity parameter is estimated online with a least-squares approach and used to compute future insulin input by minimizing a quadratic cost function to control future BG levels.
An alternative, but related, approach to prediction is to consider BG levels as discrete time series data and use models such as autoregressive integrated moving average (ARIMA) for prediction. In [71] , the authors use an ARIMA model to predict blood glucose levels and hypoglycemia. For similar purposes, in [54] , authors use an autoregressive AR(1) model. From a perspective in which the aim is to resolve the mean and variance of blood glucose levels, for the purposes of prediction, the model that we develop in this paper can be viewed as a generalized AR(1) model. A standard AR(1) model uses only the BG measurements and provides predictions based on the information obtained from this data. With the model we develop here, in addition to the blood glucose measurements, we use nutrition and external insulin data to account for non-stationarity in the environment, and calculate the effects of nutrition and external insulin on the discrete time-series by means of an underlying continuous time model. In this sense, we aim to achieve and enhance what an ARIMA process can do by using an underlying continuous-time mechanistic model to describe known, and measured, environmental factors. Moreover, by constructively formulating the functional form of a model embedded with hardcoded physiologic mechanisms, we are hoping to provide both a pathway for incorporating external physiologic knowledge-reducing the data required to estimate the model-and a modeling framework that, being based in physiology, is likely to be more interpretable to humans working in systems physiology and in a clinic.
All of these different models, and the algorithms that stem from them, demonstrate significant diversity in the dynamics of the glucose-insulin system between individuals. This highlights the importance of personalized models for parameter inference, prediction and control, using data collected from individual patients or perhaps, once more data is gathered, by clustering patients and using representative parameter settings from the appropriate cluster. Many of the models described have so many unknown parameters that it is very hard to use them in such realistic settings. Recently, some researchers have started to address the applicability of the models in the real patient-data setting [56, 11, 74] and these papers demonstrate some of the difficulties which arise. In this paper, we aim to develop a simple interpretable mathematical model that, in view of its interpretability, can be used safely for glucose prediction and control, and in view of its simplicity, can be trained on patient data. We concentrate primarily on the T2DM and ICU settings, and comment briefly on the relevance of our modeling approach for type one diabetes (T1DM).
Our Contribution
• We describe a simple, interpretable, modeling framework for prediction within the human glucose-insulin system, based on a continuous time linear, Gaussian, stochastic differential equation (SDE).
• The framework is sufficiently general to be usable within the ICU, T2DM and potentially T1DM settings.
• We demonstrate, in a train-test set-up, that the models are able to fit individual patients with reasonable accuracy; both ICU and T2DM data are used. The test framework we use is a predictive one laying the foundations for future control methodologies.
• Comparison of the data fitting for T2DM and ICU patients reveals interesting structural differences in their glucose regulation.
Outline
An outline of the remainder of the paper is as follows. In Section 2, we introduce the general continuous-time mathematical model that describes the human glucose-insulin system. Then, in Section 3, we introduce the specific versions of this model relevant in T2DM, ICU, and T1DM settings. The three model classes all derive from a single general model, and differ according to how nutrition uptake and glucose removal are represented. In Section 4, we construct the framework for stating the parameter estimation problem and its solution. In Section 5, we describe the datasets, the experiments we design for parameter estimation and forecasting, and the methods we use for parameter estimation and forecasting for the T2DM and ICU settings. Section 6 presents the numerical results on parameter estimation and forecasting along with some uncertainty quantification (UQ) results separately for T2DM and ICU settings. Finally, in Section 7, we make some concluding remarks and discuss future directions that we intend to pursue.
Continuous-Time Model
In accordance with our goal, which is to develop a highly simplified yet interpretable model, we work with a forced SDE of Ornstein-Uhlenbeck type to describe glucose evolution, together with an observation model of linear form, subject to additive Gaussian noise. The Gaussian structure allows for computational tractability in prediction since probability distributions on the glucose state are described by Gaussians and hence represented by simply a mean and variance. Note that the protocols for managing glucose depend on intervals; e.g., a goal may be to keep glucose between 80-150 mg/dl and interval deviation from this goal, e.g., 151-180 mg/dl, induce changes in the insulin dosage. This means that decisions are made based on boundaries of glycemic trajectories. Nevertheless, because glucose oscillates under continuous feeding, clinicians typically aim to ensure that the glycemic mean does not fall below 60 mg/dl or above 180 mg/dl for any length of time. The intervals are then a proxy for this balance of managing the mean and protecting against trajectories diverging too high or low at any time, including between observations. Hence accurately resolving mean and standard deviation in BG levels is extremely important. Furthermore the Kalman filter may be used to incorporate the data, and also works entirely within the Gaussian framework; and finally parameter learning, although non-Gaussian, is well-developed in the Kalman filter setting, both from the fully Bayesian and optimization (empirical Bayes) perspectives. The Ornstein-Uhlenbeck process has three contributions: a damping term which drives the BG level towards its base value at a rate which is possibly insulin dependent; a forcing representing nutritional intake and a white noise contribution, which is used to encapsulate the high-frequency dynamics as these dynamics are difficult to be resolved with sparse measurements. The presence of noise in the glucose evolution model, as well as in the data acquisition process, allows for model error which is natural in view of the the rather simple modeling framework. We obtain the following model for the evolution of blood glucose G(t):
The BG level at time t is measured in the units of mg/dl, I(t) is the rate of intravenous insulin (insulin iv) at time t in the units of U/min where U is the insulin unit, and m(t) is the meal function representing the rate of glucose intake at time t in the units of mg/(dl*min). Here, W (t) is a Brownian motion and describes variations in the BG level G(t) which are not encapsulated in the simple dampeddriven exponential decay model that we use here.
In our approach, we use the stochastic differential equation as stated in (2.1). In this model, G b represents the basal glucose value in mg/dl units and γ is the decay rate of BG level to its basal value with its own effect in the units of 1/min, β is a proportionality constant for the effect of insulin iv on the decay rate of BG level in the units of 1/U, and σ is the variance of the oscillations, which is set to be proportional to G b : σ = αG b ; this reflects empirical observations showing that the fluctuations around basal glucose values are positively correlated with the basal value itself, [1] . We will use simple models for the meal function m(t) and the insulin delivery function I(t) that will enable explicit solution of the continuous time model between events; events in our model are times at which the meal function or insulin delivery function change discontinuously, or points at which BG is measured. The precise notation will be given below. The simple structure of Brownian motion W (t) means that, when integrated, it will lead to normally distributed random variables in discrete time, with analytically calculable means and variances. The model is thus highly tractable. The equation given in (2.1) is analytically solvable, meaning that we can write a formula in continuous time that gives the BG level at any time t, the output of the system, as a function of the nutrition and insulin delivered up to time t, the inputs to the system. For computational purposes, and because data is typically available in discrete time, we need the discrete-time version of the model (2.1)-(2.2). The time discretization is defined completely by the dataset in the following sense. Let {t 
, to be the event times, which naturally identify the time discretization. In order to make use of analytical tractability of the model (2.1) and account for the fact that event times occur at discrete, irregular times, we obtain the discrete-time version by integrating (2.1) over the event-time intervals, [t k , t k+1 ), k = 0, 1, ..., N − 1, and refer to the resulting model as the event-time model.
We will exhibit the differing versions of the general event-time model for T2DM and ICU settings in more detail in the following sections, but here we make a general overarching observation about the form of the event-time model. Since the insulin iv function I(t) is a piecewise constant function, it takes a constant value for every interval [t k , t k+1 ). So, let I(t) =: i k for t ∈ [t k , t k+1 ) and so, γ(t) = γ + βi k =: γ k , for t ∈ [t k , t k+1 ). If we integrate (2.1) over [t k , t k+1 ), with use of Itô formula, 1 we obtain that
3)
where h k := t k+1 − t k and ξ k ∼ N (0, 1) independent random variables for k = 0, 1, ..., N − 1.
Event-Time Model
In this section, we show how the general continuous-time model (2.1)-(2.2) takes its specific forms for T2DM, ICU, and T1DM settings. In Sections 3.1 and 3.2, we define the specific meal function for each case and derive the final discrete-time model, which we refer to as the event-time model. The focus of our data-driven studies here are the ICU and T2DM patients, but we develop the discrete-event T1DM model here for completeness and for potential future use. The general model in (2.1) takes different forms when it is stated in different settings. For example, in the ICU setting, the meal function m(t) is a piecewise constant function reflecting the constant rate of nutrition. However, in the T2DM setting, our dataset includes the total glucose amount ingested at each meal, and we must model the time-history of the resulting glucose intake. Taking into account all of these sort of differences, we state the "event-time" version of the continuous general model in (2.1).
T2DM
In this setting, we will consider a system that is driven by nutrition. Namely, the only input to the model in its current version is the nutrition. That is, we are developing a T2DM model assuming that individuals do not inject insulin, since none of the patients in our dataset use subcutaneous insulin. However, we could easily modify the model to include injectable insulin. Note that besides incorporating the effect of injectable insulin into the model, we will also modify it to account for the use of drugs such as metformin. So, in this setting we choose to model glucose removal to occur at a constant rate γ, setting β = 0; the variable I(t), which represents the rate of insulin iv, does not enter the model at all. On the other hand, the "meal function", m(t) in this case requires to make some additional modeling decisions. In order to model the glucose input from each meal into the system, we use the difference of two exponential functions. There are two reasons for making this choice. The first is to describe the uptake of glucose into the bloodstream via ingestion through the stomach, and the second is to have a smooth function of model parameters from which we will benefit when performing parameter estimation from data. Note that using a smooth function to model glucose intake has a substantial impact on inference, and the details about the choice of this function will be discussed later in Section 7. Now, recall that {t (m) k } Km k=1 denotes the starting time of the meals over the whole time interval that we work on. Then, we define
where G k is the total amount of glucose (mg/dl) in the k th meal, and c k is normalizing constant so that
)dt = 1, for k = 1, 2, ..., K m . Also, χ A (·) is called the characteristic function and defined as follows
Therefore, the model in (2.1) becomeṡ
in the T2DM setting. In this model, the first term represents body's own effect to remove insulin from the bloodstream, the second term represents the effect of nutrition on the rate of change of BG, and the last term models the oscillations in the BG level. Integrating over [t 0 , t], we can write the analytic solution of this equation as
Note that, in practice, we need to evaluate BG level at specific time points and hence need the discrete-time model implied by the continuous time representation in (3.3). Now, by integrating (3.2) over [t k , t k+1 ) and denoting g k := G(t k ) for k = 0, 1, ..., N , we obtain
as a special case of (2.3). Also, for any fixed t k , find the meal times t 
for k = 0, 1, 2, ..., N − 1. Hence, note that in this case, we have five model parameters to be estimated: G b , γ, α, a, b. Recall that in this setting, G b represents the basal glucose value that BG level stays around starting some time after nutrition intake until the next nutrition intake.. γ represents the decay rate of BG level G b after the nutrition intake, and α is the proportionality constant in σ = α * G b , where σ represents the amplitude of the BG level oscillations. The parameters a and b entering the meal function implicitly control the time needed for the glucose nutrition rate to reach its peak value, and the time needed for this rate to return back to the vicinity of 0. Because of these simple physiological meanings, the parameters entering the event-time model are important not only for accurately capturing, and predicting, glucose dynamics based on data, but also contain implicit information about the health condition of the patient. For example, the basal glucose value is measured during some tests to check if an individual is healthy, pre-diabetic, or diabetic.
ICU
In the ICU setting real data is available for both nutrition and insulin iv. Nutrition is typically delivered through enteral feeding tube, which is a mechanism to deliver nutrition via a tube entering to the mouth and running to the gut. On the other hand, 8-10% of the ICU patients are diabetic and only 5% of those are T1DM patients. However, more than 90% of ICU patients require glycemic management and 10-20% of them experience a hypoglycemic event over the course of management. Consequently, regardless of being diabetic or non-diabetic, they are typically given insulin iv to control BG levels. For simplicity, and because it is a reasonable approximation of reality, i.e., insulin iv and tube feed are delivered at a constant rate we approximate both nutrition and insulin as piecewise constant functions. Furthermore, in contrast to the situation for T2DM, we do not set β = 0 unless patient is not delivered insulin iv. In this case {t (m) k } Km k=1 represents the change of rate times for nutrition and the meal function becomes
k+1 ), k = 0, 1, ..., K m − 1, that is directly obtained from the data set. Remember that the insulin rate function, I(t) is also a piecewise constant function, which we formulate as
where i k is the rate of insulin over the time interval [t 
In this model, the first term models the glucose removal rate with body's own effort (γ) and external insulin effect (βI(t)). The second term shows the effect of nutrition on the BG level, and the last term models the oscillations in the BG level. Now, define Γ t (v) := e − t v γ(s)ds for v ≤ t and integrate (3.8), to get the analytical solution for any t ≥ t 0 as follows
For the same reasons explained in the T2DM setting, we will put together all event times and rewrite the meal function, m(t), and the insulin function, I(t), with respect to this new discretization of the time interval. Then, once again, using the same notation, and integrating (3.8) over [t k , t k+1 ), we obtain the discrete version as follows:
as another special case of (2.3). Note that in this case, we have four model parameters to estimate: G b , γ, α, β. Remember once again, G b is the basal glucose value and γ is the decay rate of the BG level to its basal value, and α is the proportionality constant in σ = α * G b , where σ is a measure for the magnitude of the BG oscillations. Finally, β is another proportionality constant, which is used to scale the effect of insulin iv on the BG rate change appropriately. These four parameters represent physiologically meaningful quantities that could properly resolve the mean and variance of the BG level.
T1DM
Here we explain how to adjust the general model (2.1)-(2.2) for potential use in T1DM context, by appropriate selection of parameters and functions. To this end we note that it is known that for T1DM individuals glucose is removed from bloodstream by means of kidney function, as well as subcutaneous insulin. If we want to account for kidney effect on BG level, we can model this by γ term, keeping in mind that its value would be close to 0. On the other hand, if we decide to neglect this effect to have even simpler model, we may set γ = 0. Also, to account for the fact that T1DM patients cannot regulate their BG level by themselves, we cannot talk about a basal glucose value that their BG level stabilizes through. So, we set G b = 0. Moreover, the effect of injectable insulin on the BG rate of removal is known. In [17] , the insulin action of different types/brands of insulin as a function of time is shown. The plots suggest that we can use a function in the form e −c(t−t ) − e −d(t−t ) , where t is the injection time. Note that since the actual effect of insulin is known, corresponding c and d parameters could be determined easily to match the plots given in [17] in advance and hence modeling insulin does not introduce new unknown parameters to be estimated from data. However, we can still keep β parameter in the model, which would only serve to scale the insulin action to capture differences among the patients up to some level. Moreover, we could also use the meal function m(t) as defined in (3.1) in this setting, too. So, the model takes the following form.
in which c and d will be determined in advance depending on the subcutaneous insulin type/brand used. Integrated (3.11) over [t 0 ], t, we obtain the analytical solution as
where Γ t (s) := e − t s γ(u)du with γ(·) as in (3.12) . Once again, obtaining the event times {t k } N k=0 as the re-ordered collection of meal start times, insulin injection times, and BG measurement times, we can formulate the event-time version of the T1DM version of our model as follows.
solution approaches for this problem: an optimization based approach which identifies the most likely solution, given our model and data assumptions; and MCMC, which samples the distribution on parameters, given data, under the same model and data assumptions. These two solution approaches are detailed in Sections 4.2 and 4.3, respectively.
As shown in detail before, our model takes slightly different forms in the T2DM and ICU settings. In the former the model parameters to be estimated are G b , γ, α, a, b whereas in the latter the unknown parameters are G b , γ, α, β. However, we adopt a single approach to parameter estimation. To describe this approach we let the vector, θ represent the unknown model parameters to be determined from the data, noting that this is a different set of parameters in each case. Many problems in biomedicine, and the problems we study here in particular, have both noisy models and noisy data, leading to a relationship between parameter θ and data y of the form
where unknown ζ is a realization of a mean zero random variable, but its value is not known to us. The objective is to recover θ from y. We will show how our models of the glucose-insulin system lead to such a model.
Bayesian Formulation
The Bayesian approach to parameter estimation is desirable for two primary reasons: first it allows for seamless incorporation of imprecise prior information with uncertain mathematical model and noisy data, by adopting a formulation in which all variables have probabilities associated to them; secondly it allows for the quantification of uncertainty in the parameter estimation. Whilst extraction of information from the posterior probability distribution on parameters given data is challenging, stable and practical computational methodology based around the Bayesian formulation has emerged over the last few decades; see [61] . In this work, we will follow two approaches: (a) obtaining the maximum a posteriori (MAP) estimator, which leads to an optimization problem for the most likely parameter given the data, and (b) obtaining samples from the posterior distribution on parameter given data, using Markov Chain Monte Carlo (MCMC) techniques. Now let us formulate the parameter estimation problem. Within the event-time framework, let g = [g k ] N k=0 be the vector of BG levels at event times {t k } N k=0 , and y = [y k ] Ko k=1 be the vector of measurements at the measurement times {t
. By using the event-time version, and defining {ξ k } N k=0 to be independent and identically distributed standard normal random variables, we see that given the parameters θ, g has multivariate normal distribution, i.e., P(g|θ) = N (m(θ), C(θ)).
That is, if a measurement i ∈ 1, ..., K o is taken at the event time t j , j ∈ 0, 1, ..., N , then the i th row of L has all 0's except the (j + 1) st element, which is 1. Adding a measurement noise, we state the observation equation as follows:
where Γ(θ) is a diagonal matrix representing the measurement noise. Thus, we obtain the likelihood of the data, given the glucose time-series and the parameters, namely P(y|g, θ) = N (Lg, Γ(θ)).
However, when performing parameter estimation, we are not interested in the glucose time-series itself, but only in the parameters. Thus we directly find the likelihood of the data given the parameters (implicitly integrating out g) by combining (4.2) and (4.3) to obtain
where S(θ) = LC(θ)L T + Γ(θ). Since ζ has multivariate normal distribution, using the properties of this distribution, we find that given the parameters, θ, y also has multivariate normal distribution with mean Lm(θ) and covariance matrix S(θ). This is the specific instance of equation (4.1) that arises for the models in this paper. We have thus obtained P(y|θ) = N (Lm(θ), S(θ)), that is,
this is the likelihood of the data, y, given the parameters, θ. Also, since we prefer to use − log(P(y|θ)) rather than directly using P(y|θ) for the sake of computation, we state it explicitly as follows.
Moreover, by using Bayes Theorem, we write P(θ|y) = P(y|θ)P(θ) P(y) ∝ P(y|θ)P(θ).
(4.7)
Note that the second statement of proportionality follows from the fact that the term, P(y), on the denominator is constant with respect to the parameters, θ, and plays the role of a normalizing constant. From another point of view, considering (4.2) and (4.4), we see that given θ, (g, y) has multivariate normal distribution with mean and covariance matrix that could be computed from the above equations since, given θ, everything is explicitly known. Then, integrating g out, in other words, computing the marginal distribution we obtain the distribution of y|θ, which corresponds to the one stated in (4.4) . Now, to define the prior distribution P(θ) we assume that the unknown parameters are distributed uniformly across a bounded set Θ and define
where χ Θ (·) is the characteristic function, as defined above and |Θ| is the volume of the region defined by Θ. Thus, by substituting the likelihood, (4.5), and the prior distribution, (4.8), into (4.7), we formulate the posterior distribution as follows
Now, we will show how we use this posterior distribution to state the parameter estimation problem.
Optimization
In this approach, the goal is to determine parameter values, θ, which maximize the posterior distribution, P(θ|y) and is called to be the MAP estimator. Using the prior distribution as specified above, the parameter estimation problem becomes θ * = arg max Then, substituting (4.6) into (4.10), the problem will take the form
Hence, placing uniform prior distribution turns the problem of finding the MAP estimator into a constrained optimization problem. To solve this problem, we use built-in MATLAB functions, such as fmincon and multistart. fmincon is a gradient-based minimization algorithm for nonlinear functions. multistart starts the optimization procedure from the indicated number of starting points that are picked uniformly over the region defined by the constraints. It uses fmincon and other similar type of algorithms to perform each optimization process independently and provides the one that achieves the minimum function value among the result of all separate runs. With this approach, we have the opportunity to compare different optimization procedures that starts from different initial points. This provides some intuitive understanding of the solution surface and hence the estimated optimal parameters.
MCMC
Once an optimal point has been found, we may also employ the Laplace approximation [46, 50] to obtain a Gaussian approximation to the posterior distribution. The Laplace approximation is a reasonable approximation in many data rich scenarios in which all parameters are identifiable from the data, because of the Bernstein Von Mises Theorem [66] , which asserts that the posterior distribution will then be approximately Gaussian, centered near the truth and with variance which shrinks to zero as more as more data is acquired. However data is not always abundant, and not all parameters are identifiable even if it is; in this setting sampling the posterior distribution is desirable. MCMC methods are a flexible set of techniques which may be used to sample from a target distribution, which is not necessarily analytically tractable, [44, 55] . For example, the distribution P(θ|y) is the conditional distribution of the random model parameters, θ given the data, y. Even though we can explicitly formulate it as in equation (4.7), it is not always an easy task to extract useful quantities, such as posterior mean and variance, from that formula. In such cases, MCMC techniques are used to generate random samples from this target distribution and this random sample is used to obtain the desired information, which could be anything such as the mean, mode, covariance matrix, or higher moments of the parameters. Moreover, this technique is also very helpful to obtain UQ results for the estimated parameters.
In order to obtain more extensive knowledge than MAP estimator can provide about the posterior distribution of parameters given the data, θ|y, we use MCMC methods as a natural choice to sample from that distribution. Among different possible algorithms (see [27] ), we use the standard random walk Metropolis-Hastings algorithm. In order to make sure the resulting sample is indeed a good representer of the posterior distribution, we perform some diagnostics such as checking if chains for each parameter converged and if they are uncorrelated. Then, after removing the burn-in period, we compute the mean and the covariance matrix fro the remaining part of the sample. We use the mean as a point estimator for simulation and forecasting, and the covariance matrix provided valuable information to quantify uncertainty for the estimated parameters.
In general, it is hard to obtain efficient results with MCMC methods even when sampling from the joint distribution of four or five parameters, due to the issues such as parameter identification. Moreover, obtaining accurate results with this approach requires careful choice of starting point and tuning some other parameters. In general the performance of the algorithm will depend on the initial point. We tested the use of both random starting points and MAP estimators as starting point. The former enables us to detect when several modes are present in the posterior distribution; the latter helps to focus sampling near to the most likely parameter estimate and to quantify uncertainty in it. However, it is also important to note that using MAP estimator as a starting point is not helpful in all cases. More precisely, if the MAP estimator is not a global minimum but a local minimum, then the chain could get stuck around this point. Therefore, it requires careful analysis, comparison and synthesis of the results obtained with these different approaches.
Methods, Datasets and Experimental Design
In this section, we describe the datasets that we have in the T2DM and ICU settings, the experiments that we design to present our numerical results, and the methods that we follow to perform parameter estimation and forecasting. Depending on the specifics of each case and to reflect the real-life situation, we designed slightly different experiments in the T2DM and ICU settings. However, the mathematical solution approaches for parameter estimation and forecasting stay the same for both settings because we use similar mechanistic models. In this opening discussion we first describe the features that are common to both the T2DM and the ICU settings. The two following subsections 5.1, 5.2 then detail features specific to each of the two cases.
Because we use a linear, Gaussian stochastic differential equation to model the BG level, our forecast is a Gaussian characterized by its mean and standard deviation. Hence, rather than having a point estimate for the future BG levels, we obtain a normal random variable for each prediction. In testing predictions of the model it is natural to check if 1− and 2− stdev intervals around the respective means capture the true BG levels. Note that the probability of a Gaussian random variable to take values within 1− and 2− stdev regions around its mean are ∼ 68% and ∼ 95%, respectively.
We define the observational noise covariance Γ(θ), defined in (4.3), to be a diagonal matrix with form diag(Γ(θ)) := λ * Lm(θ). Whilst we could estimate λ alongside θ, from the data, we have chosen a heuristic to set it in advance. Specifically we found that above a value of around 0.3 all forecasts were very noisy and contained little predictive value; on the other hand, below 0.3 results appeared to be fairly robust to the value chosen for λ; in all the experiments presented in Section 6 we choose λ = 0.1.
T2DM
Model, Parameters, and Dataset
In this setting, we use the model (3.4) with the function m k defined as in (3.5) . Hence, there are five parameters to be estimated: basal glucose value (G b ), BG decay rate (γ), the proportionality constant (α) in σ = α * G b with σ being the measure for the amplitude of BG oscillations, and a and b, which are the parameters implicitly modeling the time needed for the rate of glucose in the nutrition entering the bloodstream to reach its maximum value and the total time needed for this rate to decrease back to 0. We assume that the prior distribution is non-informative and initially the parameters are independent, except for a constraint on the ordering of a and b. We determine realistic lower and upper bound values for each of them, define Θ := [0, 750] × [0, 5] × [0, 5] × [0.01, 0.05] × [0.01, 0.05] (in the order of G b , γ, α, a, b), and then define Θ from Θ by adding the constraint a < b. We thereby form the prior distribution as defined in (4.8) . Recall that these bounds define the constraints employed when we define the parameter estimation problem in the optimization setting for the MAP point. The set Θ is determined from clinical and physiological prior knowledge, and by simulating the model (3.2) and requiring realistic BG levels. Data are collected from three different T2DM patients. For each patient the dataset consists of the meal times, the glucose amount in the meal and BG measurements along with the measurement times. More detailed information on the dataset such as number of measurements, recorded meals, and mean glucose value over training, testing or over entire data sets can be found in Table 5 .1.
Parameter Estimation and Uncertainty Quantification
We perform parameter estimation for three patients separately. First, we estimate parameters by using data over four consecutive, non-overlapping time intervals with optimization and MCMC approaches.
Besides estimated values, we also provide UQ results. In the optimization setting, we use the Laplace approximation as discussed at the start of subsection 4.3. The optimal parameters determine the mean of the Gaussian approximation, and the inverse of the Hessian matrix becomes the covariance matrix, providing the tools for UQ. In the MCMC approach, we use the resulting random samples for UQ.
Forecasting
We adopt a train-test set-up as follows. Since the health conditions of the T2DM patients are unlikely to change over time intervals that are on the order of days, we design an experiment in which we use one week of data for training the patient-specific parameters. Then, we use the estimated parameters to form a patient-specific model and use this model to forecast BG levels for the following three weeks, using the known glucose input through the meals; this leads to a three-week testing phase. From a practical patient-centric point of view this leads to a setting in which forecasting BG levels for the following three weeks requires patients to collect BG data for only one week in every month, and then the patient-specific model will be able to capture their dynamics and provide forecasts based on nutrition intake data over the rest of the month.
ICU
Model, Parameters, and Dataset
In the ICU setting, we use the model (3.10), and there are now four parameters to be estimated: basal glucose value (G b ), BG decay rate (γ), the proportionality constant (α) in σ = α * G b , and another proportionality constant (β) to scale the effect of insulin iv on the BG level. Similar to what we did in the T2DM setting, we find realistic lower and upper bounds for the unknown parameter values and set Θ := [0, 750] × [0, 5] × [0, 5] × [0, 200] to obtain the prior distribution as defined in (4.8) . As in the T2DM case, we choose these bounds based on physiological knowledge and requiring simulated BG levels with values within the region Θ to be realistic. In this case, the dataset consists of the rate of glucose in the nutrition and the rate of insulin infusion along with the times at which there is a rate change. It also contains the BG measurements and the measurement times. Summary statistics about the data set that is used in the ICU setting can be found in Table 5 .1: Information about the data set that is used in the T2DM setting, which is collected from three different T2DM patients. Note that there is a considerable variability between the data collection behaviour of each patient, which is also reflected in the number of recorded measurements and meals. Also, recall that we intentionally used one week of data for training and the following three week of data for testing.
Parameter Estimation and Uncertainty Quantification
We use both the optimization and MCMC approaches for parameter estimation in a patient-specific manner, in this setting, too. However, for UQ, we use only MCMC to estimate the posterior mean and variance on the parameter; this is because there were cases where it was not appropriate to use the Laplace approximation, something that will be explained in more detail in Section 6.2.
Forecasting
Patients in the ICU exhibit BG time-series that are very different from T2DM patients; in particular the time-series is often non-stationary in complex ways and on different time scales. On slower time scales, patients eventually leave the ICU because their health either improves or declines. But there can be fast time scale changes too due to interventions and/or sudden health-related events, such as a stroke. These health changes will lead to changes in the best-fit parameters of the model; in other words the patient-specific model itself may change abruptly, in contrast to the T2DM case where changes in the best-fit parameters typically occurs on a much longer time-scale, and reflects gradual changes in health condition. To avoid compensating for different values of parameters over longer time intervals, and to make more accurate predictions, we use only one day of data for parameter estimation in the ICU. Moreover, to construct an experiment that reflects real-life scenarios, we need be able to estimate the model parameters with smaller size datasets than in the T2DM case, because of the imperative of regular intervention within the ICU setting, typically on a time-scale of hours. As a consequence our train-test set-up in this case differs quantitatively from the T2DM case. The training sets for each patient consist of approximately one day of data over a moving time intervals, with end points chosen to be BG measurement times. Thus, the time windows are obtained by moving the left end point to the next BG measurement time and choosing its right end point with the constraint that it contains approximately one day of data and the new time window is not contained in the previous one. So, in this case, there is a large overlap between the consecutive time windows of the training sets.
On the other hand, because of rapidly changing conditions, forecast of BG levels needs only to be accurate over shorter time-scales, too. Indeed, in general, it is important to know glycemic dynamics on the order of hours (not days) to manage the glycemic response of patients. So, for each training set, the left end point of the time window of the corresponding testing set is chosen to be the right end point of the time window of the patient's training set. Then, we choose the right end point of the test set to be the next BG measurement time. We follow the same procedure over the moving time intervals to the end of the whole dataset for each patient. Note that from a practical point of view, this experiment exhibits a real life situation in which we use only one day of data for parameter estimation and then perform forecasting for the next few hours based on the estimated parameters. Such a set-up would be desirable as a support to glycemic management of these patients.
Numerical Results
The numerical results that we present in this section demonstrate the two primary uses of the simple, yet interpretable, model introduced in this paper:
• we can achieve good accuracy in forecasting future BG levels in both the T2DM and ICU settings, and the uncertainty bands with which we equip our forecasts play an important role in this regard;
• we can learn a substantial amount about the interpretable parameters within the models, with possible clinical uses deriving from the parameter estimates, and from tracking them over time, again using the uncertainty measures that accompany them as measures of confidence.
We justify these conclusions using T2DM self-monitoring data from a previous prospective selfmanagement trial, and using retrospective ICU data extracted from the Columbia University Medical Center Clinical Data Warehouse. The combination of simple predictive model and data acquisition model accounts for the uncontrolled and complex nature of the data, including data sparsity, inaccuracy, noisiness, non-stationarity, and biases resulting from the health care process [1, 6, 35, 36, 37, 38, 42, 53] , whilst also being interpretable and leading to patient-specific parameter inference and prediction. To forecast BG for individuals we first solve the parameter estimation problem to entrain the model to the individual, and we present the numerical results in this order. Even though the our model is relatively simple physiologically it is not always identifiable, given data. For example, having two parameters, γ and β, related to BG decay rate in the ICU context made it hard to identify these parameters accurately given the sparsity of the data, the non-stationarity of the patient, and the complexity of the glycemic dynamics. Despite lack of identifiability of some parameters, parameters as estimated lead to models which are able to forecast and represent the glucose-insulin dynamics. For example, in both the T2DM and ICU cases, the UQ results along with estimated parameter values indicate that the estimates of both the basal glucose rate, G b , and the proportionality constant between the basal glucose rate and the variance of the glycemic dynamics, α, reflect realistic values with uncertainties that manage to capture future data but remain narrow enough to potentially delineate different treatment pathways. To answer whether the parameter estimates, forecasts, and uncertainty quantification are good enough to impact clinical understand and decision-making or to construct physiologically-anchored phenotypes [2, 3, 5] would require evaluation, e.g., manual chart review in conjunction with a qualitative trial of clinical decision-making or a phenotyping analysis respectively. In the absence of these analyses we will rely on face validity validation [16, 32, 69] of the forecasting and UQ capturing future measures as well as a host of quantitative measures of forecast accuracy. We also reemphasize that the parameter estimates themselves may be useful as they carry information about gradual disease progression (T2DM) and sudden changes in health condition (ICU).
T2DM
We will start by showing numerical results for parameter estimation and forecasting based on the realworld data collected from T2DM patients. These results demonstrate the effectiveness of our model in capturing the patients' BG dynamics. Specifically the effectiveness is reflected in the estimated parameter values and in the efficacy in forecasting future BG levels, using these parameters, over time periods of length up to three weeks. Figure 6 .1: Parameter estimation and uncertainty quantification in the T2DM setting. The left-hand panel is obtained with optimization and the right-hand panel is obtained with MCMC, both are in a patient-specific manner. It shows that the point estimates obtained with two approaches are very close to each other in most cases. Also the width of the 1-and 2-stdev intervals, which are obtained with Laplace approximation (in the optimization case) and directly from the approximate posterior samples (in the MCMC) setting, are also agreement with each other. In addition, obtaining estimated values that are in alignment with real physiological values, these results enforces the reliability of the parameter estimation results.
Parameter Estimation
Our numerical results exhibit three substantive pieces of evidence which support the validity of the model and its potential effectiveness for both understanding the physiologic state of an individual, and for forecasting for that individual, in the context of T2DM. First, the estimated model parameter values and their evolution over time are physiologically meaningful. That is, the estimated values reflect the patient's state as evaluated given available data. Moreover, the evolution of the estimated parameter values over time reflects changes in the patients' states in a manner consistent with both the data and what is known about the non-stationary nature of T2DM. Second, the UQ intervals for the estimated parameters are physiologically plausible and have three features that make the model potentially useful: (i) relative to the value of the estimated parameter, the UQ intervals are wide enough to provide information on the reliability of the point estimates of the model parameters (ii) the UQ intervals evolution over time, demonstrating a sensitivity to time and the ability to adapt to non-stationary patients, and (iii) the UQ intervals are narrow enough to plausibly be used to differentiate behavior choices. And third, the UQ and parameter estimation appears to be robust; different estimation methods arrive at similar results. A comparison of the estimated parameter values and corresponding UQ intervals obtained using optimization and MCMC are very similar, implying robustness of the estimates and a relative insensitivity to the estimation methodology. Together these features imply that with a reasonable inference scheme this model could potentially provide useful information for clinical decision making and deeper clinical understanding of the patient robustly.
To demonstrate that the estimated parameters are physiologically meaningful, consider Figure 6 .1 where we see the point estimates as well as UQ intervals for all parameters and all three patients obtained with optimization and MCMC methods. The estimated basal glucose, G b , values are in the ranges of ∼ 95 − 105 mg/dl, ∼ 110 − 150 mg/dl, and ∼ 105 − 125 mg/dl over the course of four weeks for patients 1, 2, and 3, respectively. These values are indeed in the expected ranges based on the BG measurements of these patients. In addition, as we will describe later in more detail, the estimated parameters are able to usefully predict the glycemic mean and variance of patients with T2DM on time-scales of around three weeks. The forecast of glycemic mean and variance in response to nutrition is limited to three weeks because the data shows non-stationary effects over longer timeintervals. Figure 6 .1 reveals parameter changes that, over four weeks, are significant enough to render predictions less reliable, whilst on a three-week time horizon they are accurate.
To show that the UQ intervals are potentially useful in practice, once again consider Figure 6 .1. The range of UQ intervals for each estimated parameter contains physiologically plausible parameter values that are tight enough to enforce the reliability of the point estimates of the parameters. To quantify this statement we computed the coefficient of variation, defined as the standard deviation over the mean. This measure is generally interpreted as a dispersion of the probability density and can be interpreted as the variability of the distribution in relation to the mean. Smaller values of coefficient of variation imply less variability or dispersion within the population and that the distribution is accumulated around the mean. When the coefficient of variability is low, point estimates of the mean are particularly meaningful and represent the population well whereas when the coefficient of variation is large, the mean is less representative of the population as a whole. Note that the population we are quantifying here is not of different patients, but rather a population of different forecasts, parameter estimates, or realizations of the stochastic model, for the same patient at a given time. For basal glucose rate, G b , and proportionality constant, α, the coefficient of variation is in the ∼ 2 − 3% band and ∼ 8 − 20% band, respectively for all three patients, implying that the mean of the estimated G b is a very good point estimator. Even though the coefficient of variation values are not as small for α, these values are still quite small and demonstrate limited dispersion. Together these results support the reliability of the point estimates that are used to form patient-specific models to describe dynamics of each patient. In addition, the evolution of these UQ intervals for each parameter over four weeks, present in Figure 6 .1, demonstrates their sensitivity to time and the model's ability to adapt and capture the non-stationarity in the dynamics of patients over time.
We can see the robustness of the estimated parameter values by comparing parameter estimates using two different methods, MCMC and optimization. The results are shown in Figure 6 .1; the left and right columns show parameter estimates using optimization and MCMC, respectively. The point estimates as well as the corresponding UQ intervals for basal glucose value, G b , and proportionality constant, α, obtained with optimization and MCMC are very close to each other. Some parameters have more variation between methods; specifically, the rate of decay to the basal glucose rate, γ, and the meal function nutrition absorption parameters a and b do show variation between the results obtained with optimization and MCMC methods. This variation does not seem to have substantial effect on the model's ability to represent patient dynamics. The overall result is a model whose ability to represent the data is relatively insensitive to parameter estimation techniques.
Forecasting
The stochastic modeling approach is simple in the sense that we have few state and parameters and the model's high-frequency dynamics are represented as a diffusion process whose centroid is governed by processes such as physiologic-driven mean reversion. In contrast, this modeling approach is complex because a stochastic process doesn't have an explicit glucose trajectory-a particular glucose value-at a given time but rather is a function that defines a glycemic distribution at every time point, e.g., with a mean and a variance. Because of this subtly, the model is both intuitive-it reflects what we know and do not know about glycemic dynamics at given, unmeasured, time-and it is foreign because there is not an explicit glycemic trajectory. However, we can construct an example glycemic trajectory, or a realization of the stochastic process by sampling the SDE-defined glycemic distribution at every time point. In another words, the realization is one of the infinitely many possible trajectories that the stochastic process could follow when it is realized. Similarly, we assume the collected measurements represent a realization of a random process that is described by the solution of our model SDE. Together these pieces form a framework within which we interpret and evaluate the model. As such, we evaluate the model along two pathways, a face validity pathway that is mostly motivated by potential clinical decision-making, and a more statistical-based pathway that is motivated by our desire to be quantitative. In a sense, both evaluations address whether the data could plausibly be generated by the model.
The first evaluation-face validity-is to consider whether the model can capture the dynamics qualitatively. Because the model's forecast is in the form of a distribution, the forecast we have to Figure 6 .3: Forecasting results in the T2DM setting obtained via models formed by using the estimated parameters with the optimization approach. In each plot, the red circles show the true BG measurements, the blue curve shows the mean of the model output, and the grey region is the estimated 2-stdev band around the mean of the model output. These forecasting results show that the proposed model mean, when equipped with confidence bands found from standard deviations, estimate the BG levels accurately, and in a patient specific way. This reinforces the claim that the model parameters could be used to provide information about the health condition of individual patients.
evaluate is anchored to the mean and standard deviation. An initial inspection of Figure 6 .2a where the red circles represent the true BG measurements and blue crosses represent one realization of the model over only the first week of the test set does indeed seem to represent the data well. Digging in more deeply, there are two observations that substantiate the face validity of the model. First, the forecasted mean of the stochastic model for BG movements captures the essence of the behavior of true BG measurements in a realistic way. And second, the forecast uncertainty as quantified using the standard deviation of the process encapsulates a large percent-94% on average-of true future BG measurements while remaining narrow enough to delineate changes in nutrition input and potentially treatment strategy. Surprisingly, the forecast uncertainty is more narrow than the empirical uncertainty while capturing more of the data, meaning that the forecast uncertainty captures the future uncertainty of the data more accurately-more narrow but more specific-than the data themselves capture their own uncertainty. This is of course possible because the model is modeling glycemic response, not just the glycemic time-series. Because the optimization and MCMC approaches produced very similar parameter estimation and hence forecasting results, we only used the MAP estimators obtained with the first week of data to form the patient-specific model for forecasting over the following three weeks.
The second evaluation quantifies how plausible it is that the data we observe could have originated from the model. We quantify this plausibility using the two-sample Kolmogorov-Smirnov (KS) test. To start, Figure 6 .2b shows the kernel density estimates obtained from the BG measurements (blue curve) and from ensemble of 100 different realizations of the estimated stochastic process (red curve) over the same time period in Figure 6 .2a. To generate the data to compute the model-based density estimate we select a sample from the distribution defined by the model at every time point. The model can also be visualized as a probability density function; for example, the kernel density estimate of a model realization is the probability density function of the distribution and the real data are shown in the right panel of Figure 6 .2. The similarity of the behavior of the estimated realization (blue crosses) with the assumed realization (red circles) of the stochastic process in Figure 6 .2a and kernel density estimates in Figure 6 .2b support the idea that both are plausible draws from the same distribution. To calculate the two-sample Kolmogorov-Smirnov (KS) test we created data sets: (i) resampled 1,000 points from the raw BG measurement data, and (ii) a realization of the estimated stochastic process over the same time period as shown in Figure 6 .2a. The two-sample Kolmogorov-Smirnov test did not reject the hypothesis that the two samples came from the same distribution with a p-value of 3.9237 * 10 −6 . This implies that our initial assumption, which is that the BG values can be described by our simplified stochastic model, is indeed a valid assumption in this setting.
Given this understanding of the model, our evaluation of BG forecasting focuses on evaluating the ability of the model to estimate and track the mean and variance of BG levels. Our model's forecast is in the form of a distribution because it is stochastic and is therefore represents the glycemic distribution at every time point. In this way, the only forecast we have to evaluate is the mean and variance. And, clinical understanding and decision-making is done relative to the mean and variance of glycemic dynamics. As such we have two key results. First, the forecasted mean of the Ornstein-Uhlenbeck process, the stochastic model for BG movements, captures the essence of the behavior of true BG measurements in a realistic way. And second, the forecast uncertainty as quantified using the standard deviation of the process encapsulates a large percent-94% on averageof true future BG measurements while remaining narrow enough to delineate changes in nutrition input and potentially treatment strategy. Surprisingly, the forecast uncertainty is more narrow than the empirical uncertainty while capturing more of the data, meaning that the forecast uncertainty captures the future uncertainty of the data more accurately-more narrow but more specific-than the data themselves capture their own uncertainty. This is of course possible because the model is modeling glycemic response, not just the glycemic time-series. Because the optimization and MCMC approaches produced very similar parameter estimation and hence forecasting results, we only used the MAP estimators obtained with the first week of data to form the patient-specific model for forecasting over the following three weeks. The mean of our glucose model represents the mean glycemic homeostasis and the mean glycemic response to nutrition. Figure 6 .3 demonstrates how this mean reflects the dynamics of true BG measurements. In this figure we estimated the model parameters using one week of data, producing a model of the glycemic homeostasis and response given nutrition input. To evaluate the forecasting ability of this model we then use this model to forecast glucose for the following three weeks. The subfigures of Figure 6 .3 show the resulting forecast of BG for patients 1, 2, and 3, respectively for the three weeks after the model was estimated. In each subfigure, red circles represent the BG measurements, the blue curve shows the mean of the Ornstein-Uhlenbeck process and the gray area is the 2-stdev band around the mean. We see that the blue curve-the proper forecast-encapsulates the behavior of the true measurements for each three patients.
Not all glycemic responses follow the mean, and forecasts carry uncertainty. One particularly important and challenging task of a forecast is accurate estimate of uncertainty. Because of the nature of our stochastic model, uncertainty is quantified naturally using the standard deviation of the model process. Figure 6 .3 demonstrate the effectiveness of the models' ability to capture relevant forecast uncertainty with two standard deviation (2-stdev) bands around the model mean; these bands capture nearly every future BG measurement. These results are further quantified in Table 6 .1 that shows summary statistics for how often the measurements were captured by the 2-stdev bands as well as the estimated standard deviation of BG measurements and the empirical standard deviation obtained directly from the raw BG measurement data. Being able to contain ∼ 90−97% of the true BG measurements in these confidence regions with a smaller model standard deviation than the empirical standard deviation for all three patients is an indicator of this model's capability in capturing the patient dynamics and hence its predictive capability. This model is providing substantial forecasting information beyond what is available given the data alone.
ICU
We now move from evaluating the model with T2DM self-management data to the more complex and difficult case of modeling and forecasting glycemic dynamics in the ICU, where non-stationarity is manifest on much shorter time-scales. Parameter estimation and prediction are, in general, harder in the ICU context because patients within the ICU typically have much more volatile physiological dynamics for at least three reasons: glycemic dynamics under continuous feeding are oscillatory, the patients are acutely ill and their health state changes quickly because of their disease state, and the patients are constantly being intervened on to help them heal. To paint a picture, 90%+ of the patients will not require insulin outside of the ICU but do during their ICU stay, and around 20% of patients have a hypoglycemic episode that would not occur when they are not acutely ill. The ICU is a much more complex forecasting and modeling setting.
Parameter Estimation
The difficulties presented in the ICU setting are reflected in our parameter estimation results. Despite these complexities, Our numerical results exhibit four substantive pieces of evidence which support the validity of the model and its potential effectiveness for both understanding the physiologic state of an individual, and for forecasting for that individual, in the context of ICU patients. First, the model captures the dynamics as meaningfully as possible based on the data. That is, the estimated model parameters are physiologically plausible and represent the observable dynamics. Second, the estimated model parameters, which have the most influence in resolving the mean and variance of the BG level, are physiologically meaningful in most of the cases, as was the case in the T2DM setting. Third, the changes in the parameter estimation results over moving time windows are realistic and reflective of the expected non-stationary behavior of ICU patients. And fourth, the UQ results show that the parameters (basal glucose rate, G b and the model standard deviation, σ), which have the most influence in resolving mean and variance of BG levels are estimated with more certainty. Having tighter bands around the point estimates for these parameters indicates the robustness of the estimation. Before we begin the evaluation, first consider Figure 6 .4, which demonstrates both the model's relative robustness and its capability of capturing the dynamics and various complexities encountered in different conditions in the ICU setting. These figures show simulated BG values for patient 4 (see Table 5 .2) over different training time windows, whose data, nutrition rate and BG measurements, are used to estimate the corresponding model parameters using the optimization approach. Here the the red curves represent the mean of the blood glucose dynamics that are assumed to be oscillatory, the amplitude of oscillations are showing in grey and are represented by the 2-stdev band around the mean, and the BG measurements are shown as red circles and the blue curve shows the tube-nutrition input rate. For simplicity we are considering patient 4 who did not need external insulin, so the tubefeed nutrition is the only driver of the BG level. Each subfigure of Figure 6 .4 shows a different training time window that is representative of different circumstances relative to our ability to estimate the basal glucose rate G b , the decay of glucose to the basal rate, γ, and the proportionality parameter that resembles the width of the glycemic dynamics, σ. Figure 6 .4a shows a situation where the BG measurements reflect the nutrition rate quite well. In this case all the estimated model parameters are physiologically meaningful and the resulting simulation is a good representative of the dynamics, as can be seen by the parameter and state estimates tracking one another. In contrast, Figures 6.4b and 6.4c demonstrate a situation where the BG measurements do not reflect the nutrition rate over the time window; this failure is seen by the lack of consistency in the movement of the parameters to one another and the nutrition rate. This failure can have one of two sources. First, if there is no change in the nutrition rate over the training time window, it is impossible to estimate the glycemic decay rate parameter, γ. Second, when changes in the BG measurements are uncorrelated with the changes in the nutrition rate, potentially due to changes in health states or other interventions, e.g., other hormone drips, it is also impossible for the model parameters to accurately reflect the physiology as Figure 6 .5: Parameter estimation and uncertainty quantification results in the ICU setting obtained with MCMC approach. In each plot, the blue curve represents the point-estimate of each parameter (mean of the resulting random samples) and the grey area is the 2-stdev band around the pointestimates (also obtained from the resulting random samples). These results show that the estimated model parameters exhibit biophysically realistic values and change relatively smoothly; this is to be expected since the consecutive (moving) time windows (each of length around one day) have a large overlap. However, the cases where there is a considerable change in the estimated parameter are also understandable because of rapid changes in the patients' health condition and/or the difficulty in extracting such information due to patients' glycemic response. On the other hand, 1-and 2-stdev bands enforces the reliability of the estimated parameters, especially, G b , α, and hence, σ, which are the most important parameters in predicting the mean and variance of BG levels. they are accounting for dynamical glucose features they were not designed to accommodate. These issues do not mean the model cannot represent and forecast the glycemic dynamics, it still is usually able to represent glycemic dynamics, but some of the parameters might lose their intended meaning. For example, in the two respective examples, despite parameter estimate issues, in both of these cases the estimated basal glucose rate, G b , and the proportionality constant, α that relates the width of the oscillations-σ = α * G b where σ is a measure for the amplitude of the BG level oscillationsare physiologically meaningful and these parameters are enough to capture the mean and variance of the BG measurements accurately. Moreover, estimated decay parameter, γ, takes an arbitrary value larger than a pre-set threshold resulting in that the mean of the model being estimated as flat. These examples are not the only cases where we observe parameter estimates that are not physiologically meaningful while at the same time the glucose forecast and modeling itself remains accurate. The other examples are all variations on the same theme; we do not have the available data to estimate a parameter accurately, or the data are behaving in a more complex manner, and in both cases, the parameters make up for these data-driven and model-driven short-comings by deviating from their normal roles to render a robust glucose forecast. It is likely that problems such as these will not be eliminated by using more complex data sets and more complex models, because full representation of the relevant processes is out of reach in such non-stationary ICU settings.
With the complexity of ICU data in mind, Figures 6.5 and 6.6 show the time course of parameter estimates for each ICU patient obtained with MCMC and optimization approaches respectively, and demonstrate how the estimated parameters are physiologically plausible. In Figure 6 .5 we show estimated basal glucose rate, G b , proportionality constant, α, and hence σ = α * G b . The mean of each parameter, as estimated using MCMC, is shown as the blue curve; the parameters are estimated for every forecasting process using data from the previous day allow us to update the model to forecast the glycemic response and states, implying a moving time window of parameter estimates. These parameter estimates are physiologically plausible for all three patients except in a small number of cases. For example, estimates of the basal glucose rate, G b , were around ∼ 110 − 150mg/dl, ∼ 120 − 180mg/dl, ∼ 120 − 180mg/dl, for patients 4, 5, and 6, respectively, all plausible values given the patient's data. As was the case for the example discussed in the first paragraph of this section, it was not possible to compute good estimates for parameters γ and β in some of the cases.
If we estimate the parameters using optimization-changing the paradigm under which we estimate parameters-we can gain further insight into complexities regarding parameter estimation. Figure 6 .6 demonstrates some variability and occasionally unrealistic estimates for basal glucose rate, G b . In Figure 6 .6 we observe times where the basal glucose rate, G b being estimated very low, too low to be plausible. The reason why the basal rate is estimated incorrectly, however, is not so complex and is in fact correctable. The time periods where the basal rate is incorrectly estimated coincide with time intervals where we cannot estimate the decay rate, γ; this problem occurs again when the nutrition rate is not changed over the course of the training period, making it impossible to estimate glycemic response to nutrition. If, over the course of the optimization, the decay rate is estimated to be too high, it negates the effect of nutrition to the BG rate. Because the model now has much less dependence on nutritional input, it makes up for this by estimating the basal rate, G b as being higher than it should be. In contrast, if the estimated decay rate, γ, is underestimated then the influence of nutrition on BG is excessive and, to make up for this, the basal rate is underestimated. In this situation we can still calculate the basal rate accurately by estimating the shifted basal rate, which is the sum of estimated basal glucose value and estimated effect of nutrition rate. This shifted basal rate is how the model is modeling the glucose in the system, and the calculation for the shifted basal rate is effectively deconvolving how the model is coping with the data insufficiency. This example demonstrates some of the ICU-specific complexity and that, despite the identifiability failure due to data sparsity, the model was robust enough able to estimate the data. And, because the model is relatively simple, this further demonstrates how we are able to pull apart the modeling inaccuracies such that we can understand and account or otherwise compensate for these model errors. In addition, the estimated α values, and hence σ = α * G b values which are the measures of the amplitude of BG In each plot, the blue stars represent the MAP estimator of the corresponding model parameter. These results provide important understanding of the system through the cases whether the data is interpretable through the model or not. When both of the basal glucose value, G b and the decay rate, γ attain physiologically plausible values, this is mostly representative of a case where the data is interpretable through the model, whereas other cases reflect when it is not possible to estimate the decay rate and how this situation propagates through the other estimated parameters. level oscillations, attain physiologically meaningful values, using the optimization approach, as well. This is important because it is generally the amplitude of oscillations that will have the largest impact on clinical decision-making. And finally, despite these difficulties, the BG dynamics were still quite accurate as we will see in the forecasting evaluation (cf Figures 6.7 and 6.8). Figure 6 .5 also shows that the time evolution of the estimated parameters is realistic within the ICU context. In ICU the training time windows move in positive (increasing time) direction increments of measurements-given a measurement the model is estimated using the previous 24 hours of data, ∼ 25 data points to forecast the future measurement whenever it comes-so that the consecutive time windows have an overlap of 20-23 hours. This means that the model varies relatively continuously between consecutive time windows. This relative continuity is reflected in Figure 6 .5 that shows the time evolution of estimated parameters for all three patients. The choice of the time window used to estimate the model faces the same problem that all moving window approaches face: short time windows imply less data and higher estimation variance and long time windows imply poor adaptability in non-stationary settings but have lower variance and ample data. This is an optimization problem we will not tackle here. Instead, we set the window size on the assumption that the patient health state defined by the parameters would not change too much over the previous 24 hours, and assumption that is usually but not always correct. Even though the health condition of the ICU patients can change rapidly, the estimated parameters do not change wildly (in most of the cases), reflecting the expectation under these settings. Nevertheless, the patients are clearly non-stationary and the observed evolution of the parameter estimates, e.g., of the basal glucose value, G b and decay rate, γ, shown in Figure 6 .4 reflect this non-stationarity.
And finally, as was the case in the T2DM setting, the model is relatively robust to the methods used to estimate it; however, as can be seen in Figure 6 .8 and inferred from the discussion above about parameters and their face validity to physiology, the ICU formulation of the model can have more complex parameter estimation issues compared to the T2DM setting. In particular, in the ICU setting there are some cases where the Laplace approximation does not work well because the parameter misfit solution surface is flat in some parameter directions -a reflection of identifiability issues. In these cases we used MCMC to provide UQ results. In general we observe that the basal glucose rate G b and the proportionality parameter related to variance, α, both allow for more robust estimation compared to the estimation of γ and β. In addition, we observe that the explicit estimation of the variance, σ (= α * G b ), is more robust than any other parameter including G b and α. This is important for clinical applications because the variance, σ, is what is used for deciding insulin doses. As a demonstration of the robustness of σ compared to G b and α, consider the estimation results for patient 4. Here we can see the 2-stdev band around the mean for σ is tighter than the 2-stdev bands for G b and α. Moreover, the spikes in the G b and α estimation balance each other, providing a smooth and robust estimation result for σ. We find this same result using the optimization approach, as can be seen in Figure 6 .6. Together this implies that our model is able to robustly estimate the amplitude of the BG level fluctuations, which again is important to clinicians. On the other hand, considering the plots for γ and β estimation, the width of the 2-stdev bands shows that we are less certain about the estimated values. Remember that both of these parameters are related to the glucose removal rate from the blood. This is, perhaps, an indicator of an identifiability issue for these parameters. But it is also true that we are indeed less certain about this physiology; glucose can be removed at different rates by different physiologic processes, e.g., liver versus adipose tissue, and we are not resolving these physiologic subsystems. Moreover, due to the non-stationary and sparse nature of the data in the ICU setting, it is harder to estimate some of the model parameters accurately. Separating these inference issues is not possible given the data presently collected in these settings. Nevertheless, the parameters that play a key role in resolving the mean and variance of the BG dynamics can be estimated accurately up to the desired level. In each plot, the red circles show the true BG measurements, the blue stars show the mean of the model output, and the grey region shows the 2-stdev band around the mean of the model output. These results are, in general, very close to those obtained using the optimization approach, and the most relevant properties are shared by them both. Obtaining similar results with another numerical solution technique based on the same mechanistic model shows the reliability of the model and estimated model parameters.
Forecasting
Forecasting results in the ICU setting are indicative of two major features of this model: (i) we can capture the trend of BG measurements through the mean of the model and (ii) we can estimate the variance of the BG measurements accurately. Once again, since resolving mean and variance of BG dynamics is central to glycemic management, these results show potential usefulness of this model in the ICU context. Figures 6.7 and 6.8 demonstrate that the forecasted mean of the model and reflect it encapsulates the essence of the behavior of BG measurements for all three patients. In each of the plots in Figures 6.7 and 6.8, the red circles show the BG measurements and the blue stars are the mean of the model, the gray region is the 2-stdev band around the mean once again obtained separately for each forecasting process with the corresponding patient-specific model. In addition to representing the trend of the BG measurements, the forecasted mean of the model is nearly identical when computed using two independent methods, reinforcing the point that the model is reliable.
To observe the effectiveness of this model in estimating the variance of the BG measurements accurately, consider Figures 6.7 and 6.8 and Table 6 .2. Figures 6.7 and 6.8 shows the ability of the models to estimate the variance in glycemic dynamics visually where a large number of true BG measurements are contained in the gray regions that represent the forecasted 2-stdev bands around the forecasted mean. These results are quantified in Table 6 .2 which contains summary statistics both for optimization and MCMC methods. We see that with one exception, MCMC model estimation for patient 4, the average model standard deviation is smaller than the empirical standard deviation of the BG measurements, yet the proportion of the BG measurements captured in these regions are in the range of 85 − 95% for all three patients with two different methods. These results demonstrate the forecasting accuracy of our model, results that make the model forecast of potential use in the ICU for glycemic management.
Conclusion
Summary of the modeling framework: In this paper, we introduce a new mathematical model that describes the glucose-insulin regulatory system in humans. The model was developed with five goals in mind: (i) to create a model anchored to real clinical data, and that given these data the model would be useful for personalized parameter estimation and state forecasting [58] ; (ii) to create a model that was interpretable in the sense that patient specific parameters may be used to explain, and quantify, basic physiological mechanisms; (iii) a model which is physiologically simple, even if it was functionally complex, to avoid parameter identifiability problems present in many existing physiological models; (iv) a model framework generalizable and adaptable to several contexts including T2DM, T1DM, and glycemic management in the ICU; and (v) a model that was amenable to a modelbased control environment.
With these goals driving the model development, the model we developed follows a somewhat different approach compared to many other glucose-insulin modeling efforts where the goals of increasing [62] or Lui et al. [45] , work to understand and resolve the nature of the fast time-scale oscillations, the model developed here incorporates these sub-day glucose fluctuations into the noise process and the parameter estimation is aimed at capturing the slower moving dynamical properties such as the evolution of the rates of glucose use and production; this is done whilst keeping their compartmentalization, and thus number of parameters, to a minimum. We do this because in many cases we do not have data to support resolution of higher-fidelity physiological processes [37] as is the case in many common real-world data collection settings. And, since our overarching goal and model validation and evaluation metrics are based on the models' ability to forecast future BG levels accurately, for the sake of computational efficiency, we end up developing a lower-fidelity model which is simple yet interpretable and anchored to physiology.
Summary of key results: The model developed here is flexible enough to enable a priori plausible models valid for T1DM, T2DM and ICU settings. Experiments with T2DM and ICU data demonstrate that this a priori plausibility is borne out a posteriori. The model has physiologically interpretable parameters, which can be estimated robustly based on real-world data. Moreover, the estimated parameter values are physiologically plausible for both the T2DM and ICU settings. Hence, the new model has demonstrable capability to capture the BG dynamics of T2DM and ICU patients; in particular it does so well enough to resolve the mean and variance of their BG levels in both retrospective and predictive modes. This feature of the model reveals its potential for use in glycemic management. It also reveals the potential for future BG level forecasting. After being trained based on one week of data, it can accurately forecast future BG levels for the following three weeks in the T2DM context. On the other hand, in the ICU context, it is capable of capturing the dynamics based on one day of data. Then, it can be used for forecasting BG levels for the following 2-4 hours. In both settings, the choice of mathematical model naturally provides confidence bands for the future forecasting of BG levels. These confidence bands are extremely helpful to have an understanding about how low and how high BG levels could be in the future, and hence for the design of glucose or insulin uptake strategies to ameliorate undesirable health effects.
Model development constrained by real world data: Restricting model development to the constraints imposed by readily available real world data is a severe, but important, restriction. We can hypothesize how physiology might work in detail, and we can envisage experiments to gather new data sets that could exist to test our hypotheses; but we have not yet exploited data that are readily available to forge an understanding of what can be explained and predicted given current data acquisition instruments, cost constraints on data acquisition and time-constraints required for realtime prediction. To help facilitate the circular process of allowing our knowledge of systems physiology to inform and impact how people and clinicians manage the health of people, and help allow the gaps in understanding at the bedside to help us choose impactful systems physiologic problems to focus our efforts on, we need a bridge between these worlds, and the bridge proposed here is through inference with data based on simple yet interpretable models. In many situations we demonstrate that this is enough to make accurate short-term forecasts; and also provides a starting point for more fundamental physiologically-based systems. A key requirement when translating the model framework to a clinical setting is quantification of uncertainty in predictions. In this context our modeling effort was a success in both T2DM and ICU settings.
Blood glucose forecasting summary: Our model works well at estimating and forecasting blood glucose mean and variation boundaries in T2DM and ICU settings. For example, the model-based forecasts have more forecasting accuracy while retaining tighter uncertainty bands compared to measures derived from the data alone. The model identifies different characteristic behaviors between T2DM and ICU patients, demonstrating both generalizability and robustness of the models with respect to forecasting. Moreover, in these two scenarios the models are able to cope with the relative pace of non-stationarity of the patients, order weeks and order days for the T2DM and ICU settings respectively. This demonstrates both the efficiency of our model and its flexibility. Given these results and the fact that the model is simple and interpretable with understandable parameters implies a potential for providing a new perspective in understanding the glucose-insulin system in humans.
Comparison of the efficacy of the model for T2DM and ICU settings: The T2DM and ICU contexts are very different settings, primarily because of the time-scales on which parameters change, and the different relative importance of external events not included in the model; this difference imposes different needs in the two settings. For example, the change of the health states of the T2DM patients are in the order of days, or even weeks, whereas health states change on the order of hours for ICU patients. Keeping these case-specific differences in mind, one obvious way to compare the effectiveness of the model in these two settings is through the forecasting results. However, unlike other fields such as atmospheric physics, biomedicine is mostly missing a standardized and normalized techniques for context-sensitive forecast verification and evaluation, especially in regard to clinical effectiveness of the forecast. Because of this gap, evaluation of the models and quantitative comparison of their potential usefulness in a context-dependent way is not possible. Regardless, it is important to emphasize that we do not expect the results for the two settings to have the same accuracy due to the characteristic differences mentioned before. More precisely, comparison of Figures 6.3, 6.7, and 6.8 shows that the mean of the model output in ICU setting does not look as close to the true BG measurements as the same comparative forecasts in the T2DM case. Once again, this situation is expected due to highly non-stationary behavior of ICU patients. However, in this setting, it could be argued that being able to forecast the variance of glycemic dynamics to identify, e.g., hypoglycemia, could be more important to capture than the dynamics with the mean model output. Developing a model that is as simple as possible but not simpler: While building the final model presented here, we started with the simplest possible representation of each process and built in complexity until the model had desired predictive capability. For example, to model the meal function in the T2DM setting, we first used an impulse function that concentrates all the ingested glucose at a single meal time instant. Numerical simulations showed that this choice was too simple to reflect reality. The source of the problem is insightful: concentrating all of the glucose in the meal at one time point, the start time of the meal, caused the corresponding simulated BG levels to increase very rapidly to very high values, which were not even on the same order as the true BG measurements, e.g., when BG measurements are in the range of ∼ 100 − 150 mg/dl, the simulated BG values are in the range of ∼ 700 − 800 mg/dl. Physiologically, it is likely that a sharp spike in glucose intake would cause a spike in BG, but it is also likely the spike would be narrow and BG would return to near normal values quickly; however a full discussion of the physiologic effects of such a dose of glucose is beyond the scope of this discussion. We then tried a simplistic solution in which we represented nutrition ingestion as a square-wave function, which was sum of constant functions that have the value
where G i is the total amount of glucose ingestion in the meal starting at time t (m) i , and T is a time-scale for transfer of glucose from stomach to blood. That is, we set
+T ] (t), and let T be a model parameter to be estimated for each patient from data. This function produced reasonable, realistic simulation results. However, the cost function we minimize to fit the model to data (see (4.11)) exhibited discontinuities related to discontinuous behaviour of the meal model with respect to T . The somewhat surprising result of this discontinuity was our inability to accurately estimate glycemic responses to nutrition. Meaning, with a square wave nutrition delivery function, inference failed. These failures led us to choose a smooth function for nutrition delivery that then led to a continuous cost function with respect to the unknown model parameters. These issues led to the meal function as defined in (3.1) that satisfies both the requirements. Meaning, the model development was driven both by the need to reconcile the model with realistic physiology and by the need to be able to preform inference with data. Similar considerations applied to other aspects of model development.
Incorporating and modeling insulin administration: complexities and choices: It was challenging to introduce the insulin IV into the model within the ICU setting, and when we did this, we had to make some choices that have consequences that we weighted against the benefits. For example, the ICU model we formulated in (3.8) has some undesirable biophysical effects because the effect of insulin IV on the BG level is only exhibited through the decay rate (γ(t)). This physiologic shorting does not impact the model's ability to predict the BG dynamics using the mean and variance of the blood glucose levels. But we feel it is important to discuss two alternative models to the one we present in (3.8) , both of which are arguably more biophysically realistic, specifically: It is known that if the externally delivered insulin amount is higher than required, then patients become hypoglycemic. In terms of the mathematical models ((3.8), (7.1), (7.2)) we are comparing here, this means that blood glucose level (G(t)) could become so small, even less than the basal glucose value (G b ). The models (7.1) and (7.2) can accommodate such a situation. More precisely, if we set insulin IV (I(t)) to be a high value, the glucose value, G(t), starts decreasing and after a while it attains values smaller than the basal glucose value. However, in model (3.8) , the smallest value that G(t) can take in this situation is the basal glucose value, G b , and the effect of insulin IV to the blood glucose rate is only through the decay rate, i.e., how fast BG moves through the basal glucose value. Nonetheless, after running experiments with these two alternative models, and the model (3.8) adopted in this paper, we determined the latter to be the most effective for the purposes of accurate forecasting and so it is used for the numerical results presented here. It provided more realistic parameter estimation results for the basal glucose values, G b , and helped to reduce an identifiability problem between the γ and β parameters; and it produced slightly better future BG level forecasting results in the sense of the proportion of the true BG measurements captured in the 2-stdev bands. Table (7.1), provides a comparison of those proportions of the BG measurements that are contained in the 2-stdev bands around its mean obtained with the three different models. Note that patient 4 is not included in that table since this patient was not delivered any insulin IV during their stay at the ICU, and hence all three models collapses to the same model, which is the model obtained by setting β = 0 in all of them. Table 7 .1: Percentages of the true BG measurements included in the forecasted 1-and 2-stdev bands, in the ICU setting obtained with three different versions of the ICU model. Although the percentages are close to each other, this table shows that model (3.8) works better than the models (7.1) and (7.2) in the sense of capturing the true measurements in the forecasted confidence bands.
Generalizability of parameter estimation: Finally, a careful investigation of the estimated parameters and simulated BG levels in the ICU context shows that we can estimate parameter values that represent the BG levels very well when the true BG measurements are interpretable with the model we use for all three models, (3.8), (7.1), and (7.2). That is, if measured BG values are responsive to the changes in the rate of nutrition and insulin IV, then the BG simulations with the estimated parameters based on this data provide a very good representation of the dynamics. However, if the BG level behavior is not driven by the nutrition and the insulin IV rates, i.e., if its response is driven by other factors such as stress-induced counter-regulatory hormone levels, then the model-estimated mean is estimated to be almost-constant. This mean estimate is still good as a representation of the average of BG measurements and the variance of the measurements are still estimated accurately enough that the 2-stdev band around the mean envelopes nearly every BG measurement. For for all patients in all disease cases, independent of parameter estimation complexities, we obtain good estimates of the forecast mean and variance of the BG levels we achieve with the model are likely accurate enough to be helpful in clinical settings.
Outlook: The model we have developed has demonstrable predictive capability and discriminates between data sets in a patient-specific manner. Yes it has some limitations, which give space for future development, and also suggests some natural next-step applications. We outline a number of possible future directions. Glycemic control: Given our model construction, an obvious next step is to formulate the work on the control problem where we determine estimates of the input ranges of nutrition and insulin, necessary to keep the output, here BG, in a desired target range. This is a similar approach to something like the artificial pancreas/beta-cell project, but the inputs would include nutrition, the settings would include T2DM and ICU glycemic management, and the goal would not be a closed loop but rather an open loop system. Parameter estimation short-comings and advancement: In T2DM setting, the estimation results with optimization and MCMC approaches for the parameters a and b used to define the rate of appearance and absorption of glucose produce conflicting results. In the ICU setting, we observe some identifiability issues for the parameters modeling glucose removal with body's own effort and with insulin IV. We plan to address these issues in future. Key questions are whether different parameter estimation techniques can resolve the problems, or whether further data is required, and if so which data, and more fundamentally whether the model used is appropriate for the data. A related issue is the possibility of using mixed effects models [60, 68] in order to share common information in different patient data sets, whilst also retaining the advantages of patient specific learning. Comparison with more complex models: In order to have a better understanding about the effectiveness of this model to encapsulate BG dynamics and resolve the mean and variance of BG levels, we plan to compare it with more complex models, such as a second order linear SDE (which would allow for oscillatory dynamics but retain the advantages of linearity and Gaussianity exploited here) and the Ultradian model [62] (which is a widely-accepted physiogically based model). Such a comparison would happen within design similar to what we used in this paper for both T2DM and ICU context. Furthermore in the situation where control machinery has been added to the model, we can evaluate the various model's effectiveness in a control-based setting. Phenotyping: Because the parameters of our model are interpretable and track physiology reasonable well, we could potentially use the model parameter estimates for phenotyping studies, [2, 3, 5] . Meaning, we could estimate parameter for individuals in a given health state, establishing an inferred phenotype for the patient, and then relate this phenotype to other external health features or cluster the patient phenotypes in an effort to find structure among the inferred physiology. We have deemed efforts such as this high-fidelity phenotyping [37] and believe that this model has the potential to be used to these ends.
Exploiting model error to understand physiology: It is known that BG levels are mainly driven by the carbohydrates, however, there are also other factors that impact glucose levels. A partial list of particularly interesting features that impact BG levels and are of practical interest include macronutrients other than carbohydrates, exercise, sleep, and stress levels of patients. The presence of these features will induce systematic forecasting errors allowing us to use machine learning to explore the statistical relationship between these factors and BG levels. This would give us a systematic platform for potentially furthering the understanding of the glucose-insulin system and result in more accurate parameter estimation and forecasting. Further model generalization to include other glucose-data driven situations: We have not investigated how our model might work given oral glucose tolerance test (OGTT) data. The OGTT is one of the standard settings for glucose-insulin model development and potential use; we know of only one model that currently generalized to both OGTT and clinical data [31] and we would like to add our model to this list. T1DM: It would be interest to test our proposed modeling framework on T1DM data. The time-scales of health progression here are more similar to those of T2DM than the ICU setting, giving hope that the method might have similar predictive capability in this setting. We plan to pursue a number of the research directions outlined here in the immediate future.
